Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy and residual lesions irradiation of esophageal squamous cell carcinoma.
Metastatic Esophageal Squamous Cell Carcinoma
DRUG: TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）
Overall survival (OS), time from enrollment to patients death, up to 24 months|Progression-free survival (PFS), time from disease progression or patient death, up to 12 months
overall response rate (ORR), complete response plus partial response, up to 12 weeks|toxicities, toxicities according to CTCAE 5.0, up to 12 weeks
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy and residual lesions irradiation of esophageal squamous cell carcinoma.